Trials / Recruiting
RecruitingNCT06511401
Informing Pain Treatment Using Pharmacogenomic Analysis
C-PAIN: Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Pharmacogenomic (PGx) results. | These results are designed to provide specific dosing information based on the participant's unique genetics/genomics. |
Timeline
- Start date
- 2024-07-30
- Primary completion
- 2028-01-07
- Completion
- 2028-03-31
- First posted
- 2024-07-22
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06511401. Inclusion in this directory is not an endorsement.